ArticleBreast cancer research and treatment2026
Discrimination, spectrum, and clinical utility: ICG lymphography drainage time in axillary staging.
Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This Correspondence responds to the prospective study by Anuszkiewicz et al., which assessed dynamic indocyanine green (ICG) lymphography drainage time as a marker of axillary nodal burden. We raise three methodological points relevant to how the results should be read. First, the cohort included only patients selected for axillary lymph node dissection, so it represents a narrow, non-representative spectrum in which discrimination tends to be optimistic; the reported area under the curve of 0.995 was obtained without internal or external validation. Second, an ipsilateral-to-contralateral ratio may be more transportable than the absolute threshold that was used. Third, discrimination is not the same as clinical utility, which also depends on calibration and net benefit. We outline directions for validation and future study.
Indexed as
Identifiers
42360511What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.